A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...